ondansetron has been researched along with Melanoma in 8 studies
Ondansetron: A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties.
Melanoma: A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445)
| Excerpt | Relevance | Reference |
|---|---|---|
| " Patients received an anti-nausea regimen of dexamethasone with ondansetron or granisetron." | 9.09 | The effect of tamoxifen and cisplatin on the disease-free and overall survival of patients with high risk malignant melanoma. ( Baron, PL; Cole, DJ; Maize, JC; McClay, EF; McClay, ME; Metcalf, JS; Monroe, L; O'Brien, PH, 2000) |
| "The anti-emetic effect of ondansetron in cisplatin induced nausea and vomiting was studied in a randomized cross-over trial in 52 patients." | 9.07 | [Anti-emetic effect of ondansetron in cisplatin induced nausea and vomiting--a randomized clinical trial]. ( Zeng, WY, 1992) |
| "The antiemetic activity of ondansetron (Zofran, Glaxo Pharmaceuticals, Research Triangle Park, NC) was evaluated in 25 patients with recurrent melanoma who were treated sequentially with dacarbazine (DTIC), vinblastine, and cisplatin." | 7.68 | Efficacy of ondansetron against nausea and vomiting caused by dacarbazine-containing chemotherapy. ( Hodges, C; Legha, SS; Ring, S, 1992) |
| "Delayed emesis has not been seen during the antiemetic therapies." | 6.67 | [Nausea and vomiting in cytostatic therapy of melanoma patients with the use of metoclopramide and corticosteroid or ondansetron]. ( Baki, M; Czeglédi, F, 1994) |
| " Patients received an anti-nausea regimen of dexamethasone with ondansetron or granisetron." | 5.09 | The effect of tamoxifen and cisplatin on the disease-free and overall survival of patients with high risk malignant melanoma. ( Baron, PL; Cole, DJ; Maize, JC; McClay, EF; McClay, ME; Metcalf, JS; Monroe, L; O'Brien, PH, 2000) |
| "The anti-emetic effect of ondansetron in cisplatin induced nausea and vomiting was studied in a randomized cross-over trial in 52 patients." | 5.07 | [Anti-emetic effect of ondansetron in cisplatin induced nausea and vomiting--a randomized clinical trial]. ( Zeng, WY, 1992) |
| " We describe a patient with metastatic melanoma who developed a multifocal FDE to paracetamol, tropisetron and ondansetron during chemoimmunotherapy with interleukin 2 (IL-2) and dacarbazine." | 3.70 | Multifocal fixed drug eruption to paracetamol, tropisetron and ondansetron induced by interleukin 2. ( Bernand, S; Burg, G; Dummer, R; Scheidegger, EP, 2000) |
| "The antiemetic activity of ondansetron (Zofran, Glaxo Pharmaceuticals, Research Triangle Park, NC) was evaluated in 25 patients with recurrent melanoma who were treated sequentially with dacarbazine (DTIC), vinblastine, and cisplatin." | 3.68 | Efficacy of ondansetron against nausea and vomiting caused by dacarbazine-containing chemotherapy. ( Hodges, C; Legha, SS; Ring, S, 1992) |
| "Delayed emesis has not been seen during the antiemetic therapies." | 2.67 | [Nausea and vomiting in cytostatic therapy of melanoma patients with the use of metoclopramide and corticosteroid or ondansetron]. ( Baki, M; Czeglédi, F, 1994) |
| "Ondansetron or droperidol was given intravenously, 30 min prior to the first dose of IL-2 and then every 8 h for the duration of IL-2 treatment." | 2.67 | A randomized double-blinded comparison of the antiemetic efficacy of ondansetron and droperidol in patients receiving high-dose interleukin-2. ( Cole, DJ; Kim, H; Rosenberg, SA; Steinberg, SM; Weber, JS, 1994) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (62.50) | 18.2507 |
| 2000's | 2 (25.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Barzegar-Fallah, A | 1 |
| Alimoradi, H | 1 |
| Dunlop, JL | 1 |
| Torbati, E | 1 |
| Baird, SK | 1 |
| Czeglédi, F | 1 |
| Baki, M | 1 |
| Kim, H | 1 |
| Rosenberg, SA | 1 |
| Steinberg, SM | 1 |
| Cole, DJ | 2 |
| Weber, JS | 1 |
| Iglesias, ME | 1 |
| España, A | 1 |
| Redondo, P | 1 |
| Quintanilla, E | 1 |
| McClay, EF | 1 |
| McClay, ME | 1 |
| Monroe, L | 1 |
| Baron, PL | 1 |
| O'Brien, PH | 1 |
| Metcalf, JS | 1 |
| Maize, JC | 1 |
| Bernand, S | 1 |
| Scheidegger, EP | 1 |
| Dummer, R | 1 |
| Burg, G | 1 |
| Legha, SS | 1 |
| Hodges, C | 1 |
| Ring, S | 1 |
| Zeng, WY | 1 |
4 trials available for ondansetron and Melanoma
| Article | Year |
|---|---|
[Nausea and vomiting in cytostatic therapy of melanoma patients with the use of metoclopramide and corticosteroid or ondansetron].
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents; Drug Therapy, Combination; Female; Huma | 1994 |
A randomized double-blinded comparison of the antiemetic efficacy of ondansetron and droperidol in patients receiving high-dose interleukin-2.
Topics: Adult; Aged; Carcinoma, Renal Cell; Droperidol; Female; Humans; Interleukin-2; Lymphoma, Non-Hodgkin | 1994 |
The effect of tamoxifen and cisplatin on the disease-free and overall survival of patients with high risk malignant melanoma.
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Ci | 2000 |
[Anti-emetic effect of ondansetron in cisplatin induced nausea and vomiting--a randomized clinical trial].
Topics: Adult; Aged; Antiemetics; Breast Neoplasms; Cisplatin; Female; Humans; Lung Neoplasms; Male; Melanom | 1992 |
4 other studies available for ondansetron and Melanoma
| Article | Year |
|---|---|
Serotonin type-3 receptor antagonists selectively kill melanoma cells through classical apoptosis, microtubule depolymerisation, ERK activation, and NF-κB downregulation.
Topics: Antiemetics; Apoptosis; Down-Regulation; Humans; Melanoma; Molecular Docking Simulation; NF-kappa B; | 2023 |
Fixed drug eruption secondary to ondansetron.
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Drug Eruptio | 1995 |
Multifocal fixed drug eruption to paracetamol, tropisetron and ondansetron induced by interleukin 2.
Topics: Acetaminophen; Adult; Analgesics, Non-Narcotic; Antiemetics; Drug Eruptions; Drug Interactions; Huma | 2000 |
Efficacy of ondansetron against nausea and vomiting caused by dacarbazine-containing chemotherapy.
Topics: Adolescent; Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dac | 1992 |